? Two-and-a-half years after Pfizer stepped up to seed the biotech startup AnTolRx, the pharma giant has stepped in to take their option on an immune tolerance therapy for Type 1 diabetes. Based on the lab work of Francisco Quintana, a professor of neurology at Brigham and Women’s Hospital in Boston — who’s specialized in antigen-specific tolerance — AnTolRx has been working on a pipeline of immune tolerance therapies for autoimmune and inflammatory ailments. The biotech is picking up an unspecified upfront payment in the deal.
? As a group of industry vets gather at Secura Bio to commercialize cancer therapies around the world, Athyrium Capital Management has jumped in to provide the funds th